Key Drivers and Opportunities in the Alzheimer’s Drugs Market: Insights into Trends and Growth
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Long-Term Growth Rate is Expected for the Alzheimer’s Drugs Market Between 2025 and 2034?
The market size for Alzheimer’s medications has seen significant expansion in the past few years. It is projected to increase from $9.33 billion in 2024 to $10.19 billion in 2025, with a compound annual growth rate (CAGR) of 9.1%. The growth observed in the historic period could be associated with an increase in Alzheimer’s disease occurrences, together with enhancements in disease comprehension mechanisms, investments dedicated to research and development, worldwide health schemes, and an increase in public enlightenment and education.
The market for Alzheimer’s drugs is predicted to experience robust expansion in the coming years. It is projected to attain a value of $14.47 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 9.2%. This expansion during the forecast period is due to factors such as the use of precision medicine, concentration on disease alteration, the determination and validation of biomarkers, the development of drugs centred around patients, and the emphasis on non-pharmacological solutions. Key trends for the forecast period encompass various therapeutic strategies, digital health innovations, regenerative medicine, enhancements in diagnostic technologies, the use of artificial intelligence (AI) in drug finding, and partnerships and collaborations.
Which Macro and Microeconomic Factors Are Accelerating the Growth of the alzheimer’s drugs Market?
The escalating rates of Alzheimer’s disease are projected to fuel the expansion of the market for Alzheimer’s drugs. Alzheimer’s disease, a neurological condition that progressively gets worse, leads to brain atrophy and cell death. Alzheimer’s medication aims to address memory loss, reasoning challenges, and issues faced in daily life. These drugs can improve the patient’s quality of life and aid in retaining autonomy. For example, the Alzheimer’s Association—a U.S.-based nonprofit focused on Alzheimer’s care, support, and research—reported in May 2024 that the count of Americans aged 65 and above with an Alzheimer’s dementia diagnosis increased from 6.5 million in 2022 to a projected 6.9 million in 2024. Consequently, the growing rates of Alzheimer’s disease are propelling the expansion of the market for Alzheimer’s drugs.
Request Your Free Alzheimer’s Drugs Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp
What Are the Key Firms That Are Driving Transformation in the Alzheimer’s Drugs Market?
Major companies operating in the alzheimer’s drugs market include:
• AbbVie Inc._x000D_
• Daiichi Sankyo Company Limited_x000D_
• F Hoffmann-La Roche AG_x000D_
• Merck & Co Inc._x000D_
• Novartis AG_x000D_
What Current Trends in the Alzheimer’s Drugs Market Should Industry Players Pay Attention To?
Leading firms in the Alzheimer’s drugs market are pioneering novel products like amyloid plaque-targeting therapy to enhance treatment alternatives and amplify patient results. This therapeutic strategy in Alzheimer’s disease treatment emphasizes minimizing or averting the build-up of amyloid-beta plaques in the brain. For example, Eli Lilly and Company, an American pharmaceutical enterprise, received authorization for Kisunla (donanemab-azbt) from the FDA, an American federal organization tasked with defending public health, in June 2024. Kisunla (donanemab-azbt) is the exception being the one and only amyloid plaque-targeting therapy for early symptomatic Alzheimer’s disease. It functions by assisting the body in eliminating surplus amyloid plaques from the brain, which are tied to cognitive degeneration in Alzheimer’s patients. This treatment is given as an intravenous infusion every four weeks. The starting dose comprises 700 mg for the initial three doses, which later shifts to 1400 mg. Kisunla is precisely prescribed for adults in the early stages of Alzheimer’s disease, with mild cognitive impairment (MCI) and mild dementia, given that they have a confirmed presence of amyloid pathology.
Pre-order Your Report for Quick and Easy Delivery!
https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report
Which Key Segments Define the Structure of the Alzheimer’s Drugs Market and Their Growth Potential?
The alzheimer’s drugs market covered in this report is segmented –
1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Application: Early To Moderate Stages, Moderate To Severe Stages
Subsegments:
1) By Donepezil: Oral Tablets, Oral Solution
2) By Rivastigmine: Oral Capsules, Oral Solution, Transdermal Patches
3) By Galantamine: Oral Tablets, Oral Solution, Extended-Release Capsules
4) By Memantine: Oral Tablets, Oral Solution, Extended-Release Capsules
What Regions Are Driving Expansion in the Alzheimer’s Drugs Market?
North Americawas the largest region in the Alzheimer’s drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the Alzheimer’s drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
How Is the Alzheimer’s Drugs Market Categorized and Defined in the Industry?
Alzheimer’s drugs refer to drugs that aid in managing memory loss, issues with thinking and reasoning, and daily functioning. These drugs are used to treat Alzheimer’s disease, a brain disorder that causes memory, reasoning, and learning to gradually diminish.
Browse Through More Similar Reports By The Business Research Company:
Cardiovascular Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report
Alzheimer’s Disease Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report
Pharmaceutical Drugs And Biologics Logistics Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
